omiloxetine

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone

| image = Omiloxetine.svg

| image_class = skin-invert-image

| CAS_number = 176894-09-0

| CAS_supplemental =

| ATC_prefix = None

| ATC_suffix =

| PubChem = 3047803

| ChemSpiderID = 2310120

| UNII = H8YI0SSF7B

| ChEMBL = 2105290

| C=27 | H=25 | F=2 | N=1 | O=4

| smiles = Fc1ccc(cc1)C(=O)CN3CC[C@H](c2ccc(F)cc2)[C@H](C3)COc4ccc5OCOc5c4

| StdInChI = 1S/C27H25F2NO4/c28-21-5-1-18(2-6-21)24-11-12-30(15-25(31)19-3-7-22(29)8-4-19)14-20(24)16-32-23-9-10-26-27(13-23)34-17-33-26/h1-10,13,20,24H,11-12,14-17H2/t20-,24-/m1/s1

| StdInChIKey = FAHGZANUNVVDFL-HYBUGGRVSA-N

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| pregnancy_category =

| legal_status =

| routes_of_administration =

| density = 1.3±0.1

| boiling_point = 587.2

| melting_point = 228.65

| solubility = 0.0015

}}

Omiloxetine (omiloextinum, omiloxetino INN){{cite journal | journal = WHO Drug Information | volume = 10 | issue = 4 | pages = 212–213 | date = 1996 | url =https://www.who.int/medicines/publications/druginformation/innlists/PL76.pdf | title = Proposed INN: List 76 }} was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.{{cite web | url = http://business.highbeam.com/436989/article-1G1-139327925/omiloxetine-ferrer-licensing-offer-worldwide | archive-url = https://web.archive.org/web/20160307142131/https://business.highbeam.com/436989/article-1G1-139327925/omiloxetine-ferrer-licensing-offer-worldwide | url-status = dead | archive-date = 2016-03-07 | title = Omiloxetine - Ferrer licensing offer, worldwide | vauthors = Terencio J | work = R & D Focus Drug News | date = 2005-12-05 | access-date = 2012-05-19}}{{cite web | url = http://business.highbeam.com/436989/article-1G1-110935603/omiloxetine-ferrer-partnering-opportunity-worldwide | archive-url = https://web.archive.org/web/20160307095303/https://business.highbeam.com/436989/article-1G1-110935603/omiloxetine-ferrer-partnering-opportunity-worldwide | url-status = dead | archive-date = 2016-03-07 | title = Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data | vauthors = De Lecea C | work = R & D Focus Drug News | date = 2003-12-08 | access-date = 2012-05-19}}

Rafael Foguet also patented Abaperidone.